Alembic Pharma Reports Robust Q2 FY26 Performance with 23% Net Profit Growth

Alembic Pharmaceuticals Limited (Alembic Pharma) has announced strong financial results for the second quarter of fiscal year 2026, demonstrating significant growth across key financial metrics.

Financial Highlights

Metric	Q2 FY26	Q2 FY25	YoY Change
Net Profit	₹1.85 billion	₹1.50 billion	23.33%
Revenue	₹19.10 billion	₹16.48 billion	15.90%
EBITDA	₹3.15 billion	₹2.40 billion	31.25%
EBITDA Margin	16.50%	14.56%	194 bps

Alembic Pharma delivered a robust quarterly performance, with consolidated net profit rising to ₹1.85 billion from ₹1.50 billion in the same quarter last year, marking a substantial 23.33% year-over-year increase.

The company's revenue showed strong growth, reaching ₹19.10 billion compared to ₹16.48 billion in the corresponding period of the previous year, representing a 15.90% increase. This revenue growth indicates solid demand for the company's pharmaceutical products.

Operational Performance

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) saw a significant improvement, growing to ₹3.15 billion from ₹2.40 billion year-over-year, reflecting a 31.25% increase. This growth in EBITDA outpaced revenue growth, suggesting improved operational efficiency.

The EBITDA margin expanded by 194 basis points, reaching 16.50% compared to 14.56% in the same quarter last year. This margin expansion indicates the company's ability to manage costs effectively while growing its top line.

Board Meeting Outcome

As per the LODR data, the Board of Directors of Alembic Pharmaceuticals Limited approved the Unaudited Financial Results for the quarter and half year ended 30th September, 2025, at its meeting held on 4th November, 2025. The meeting commenced at 12 Noon and concluded at 2:25 p.m.

The company has submitted consolidated and standalone unaudited financial results, including statements of assets and liabilities and cash flow statements, for the quarter and half year ended 30th September, 2025, to the stock exchanges.

Alembic Pharma's strong performance in Q2 FY26 reflects its resilience in the competitive pharmaceutical market. The company's ability to increase profitability while expanding its revenue base positions it well for the coming quarters.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.20%	+0.69%	+0.18%	-8.27%	-16.07%	-7.78%

Alembic Pharmaceuticals Limited (Alembic) has achieved a significant milestone in its US market expansion strategy. The company announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ticagrelor Tablets, 60 mg.

Key Highlights

Alembic Pharma received USFDA final approval for Ticagrelor Tablets, 60 mg
The approved ANDA is therapeutically equivalent to AstraZeneca's Brilinta Tablets, 60 mg
Ticagrelor Tablets have an estimated market size of US$ 236 million for twelve months ending June 2025
Alembic's US sales have reached $236 million

Product Details

Ticagrelor tablets are indicated for several cardiovascular conditions:

Reducing the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction
Reducing the risk of stent thrombosis in ACS patients who have been stented
Reducing the risk of a first myocardial infarction or stroke in patients with coronary artery disease at high risk
Reducing the risk of stroke in patients with acute ischemic stroke or high-risk transient ischemic attack

Market Impact

The approval of Ticagrelor Tablets, 60 mg, opens up a significant market opportunity for Alembic. According to IQVIA data, the estimated market size for this drug is US$ 236 million for the twelve months ending June 2025. This approval complements Alembic's previous final approval for Ticagrelor Tablets, 90 mg, further strengthening its cardiovascular product portfolio.

Alembic's ANDA Approvals

With this latest approval, Alembic has achieved a cumulative total of 227 ANDA approvals from the USFDA, including:

Approval Type	Count
Final Approvals	206
Tentative Approvals	21
Total ANDA Approvals	227

Company Overview

Alembic Pharmaceuticals Limited, founded in 1907, is a vertically integrated research and development pharmaceutical company. The company specializes in manufacturing and marketing generic pharmaceutical products globally. Alembic's state-of-the-art research and manufacturing facilities have received approvals from regulatory authorities of many developed countries, including the USFDA.

In India, Alembic is recognized as one of the leaders in branded generics, with a field force of over 5,500 representatives marketing its well-recognized brands to doctors and patients.

This latest USFDA approval for Ticagrelor Tablets reinforces Alembic's commitment to expanding its presence in the US generic pharmaceutical market and demonstrates its capabilities in developing complex generic formulations.